Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2019

View Archived Issues

TFEB initiates fat cell browning

Diabetes drug eases nicotine withdrawal

SHR-4640: a potential new hyperuricemia treatment option

First-in-class fusion inhibitor against diverse and multidrug-resistant HCV strains presented

Mouse-human chimeric anti-CXADR antibody shows antitumor activity in prostate and SCLC models

Results from multiple phase III studies of anemia treatment roxadustat presented

First patient dosed in phase I/II study of the bicycle toxin conjugate BT-5528

First-in-human data for ASN-007 presented

Urinary TIMP2 and IGFBP7 as early biomarkers to predict drug induced AKI

MG-1131, a novel anti-TIGIT monoclonal antibody with promising in vitro efficacy

Phase I data reported for FPT-155 in patients with advanced solid tumors

Anti-LAG-3 monoclonal antibodies described by Pharmaexplorer, Shanghai Pharmaexplorer

KINE-101, a novel synthetic peptide for rheumatoid arthritis

AlaMab Therapeutics discloses connexin-43 antibodies

Sumitomo Dainippon Pharma patents mGlu2 receptor negative allosteric modulators

Shanghai Leadopharma Technology presents antiepileptic compounds

Sichuan Kelun-Biotech Biopharmaceutical identifies new arginase-1 inhibitors

Phase I/II study of DF-1001 in advanced HER2-expressing sold tumors begins dosing

Bacteriophage "cocktail" fights drinking sequelae, PSC

Phase IIa study of THX-110 in obstructive sleep apnea meets primary endpoint

Pivotal study of Nucala in hypereosinophilic syndrome meets primary endpoint

SQZ-PBMC-HPV begins phase I study in HPV+ recurrent, locally advanced or metastatic solid tumors

Daiichi Sankyo opens enrollment for phase II study of valemetostat in relapsed/refractory ATL

Kiadis terminates development of ATIR-101, refocuses on NK-cell therapy platform

New phase II trial evaluates KN-019 in rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...